Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 244 posts found.

robin_washington

Gilead’s CFO and Executive Vice President to depart in 2020

May 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …

Appointment
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 3, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, Gilead, autism, dementia, opioids, pharma

This week was marked by the failure of two Phase 3 trials after both Eli Lilly and Gilead suffered from …

News
robin_washington

Gilead’s CFO and Executive Vice President to depart in 2020

May 1, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, appointment, pharma

Gilead has announced that Robin Washington, the company’s Senior Vice President and Chief Financial Officer of more than a decade, …

News

Gilead subsidiary Kite Pharma to open CAR-T manufacturing facility in Maryland

April 29, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Gilead, Manufacturing Facility, Maryland, kite pharma

Gilead Sciences subsidiary Kite Pharma has announced plans to open a new CAR-T manufacturing facility in Frederick County, Maryland (US). …

News
gilead-sciences

Gilead’s selonsertib crashes at Phase 3 in NASH

April 26, 2019
Medical Communications, Research and Development, Sales and Marketing Gilead, nash, pharma, selonsertib

Gilead has broken the news that its apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib failed to meet its primary endpoint …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 18, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma

This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

April 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas, BMS, Eisai, Gilead, MSD, Pfizer, ViiV, indivior

This week was an excellent week for recommendations and approvals after Eisai, MSD, Pfizer, BMS and ViiV scored wins. Meanwhile …

News
gilead-sciences

Gilead to lay off one fifth of sales force

April 11, 2019
Sales and Marketing Gilead, Jobs, Letairis, Ranexa, redundancy, sales

Gilead Sciences is preparing to lay off around a fifth of its salesforce in anticipation for the expiry of patents …

News

Gilead accused of ripping off US taxpayers

March 28, 2019
Medical Communications, Sales and Marketing CDC, Gilead, HIV, PrEP, Truvada, US government, patents

Gilead have been accused of ‘ripping off’ US taxpayers after the firm was revealed to have generated $3 billion in …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

March 8, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Biogen, Gilead, HIV, Novartis, Scott Gottlieb, top 10

HIV hit the headlines this week after it was announced that a British man known only as the ‘London Patient’ …

News
gilead-sciences

Gilead’s Biktarvy maintains HIV suppression for 48 weeks in children and adolescents

March 7, 2019
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has lifted the curtain on new Phase 2/3 efficacy data for Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 …

News
scotland

Gilead’s CAR-T therapy Yescarta rejected for NHS use in Scotland

February 12, 2019
Manufacturing and Production, Sales and Marketing CAR-T, Cancer, Gilead, NHS, Scotland, Yescarta, kite pharma

It’s bad news for Scottish patients living with aggressive forms of non-Hodgkin lymphoma (NHL) as it emerges that the Scottish …

News
gilead-sciences

Gilead shares drop 4% after failure of NASH drug to meet primary endpoint

February 12, 2019
Manufacturing and Production Gilead, Shares, fatty liver disease, nash, selonsertib

Gilead’s treatment for the progressive fatty liver disease, NASH, has failed to meet its primary goal in a phase 3 …

News
gilead-sciences

Gilead inks $1.8 bn deal with immuno-oncology biotech Agenus

December 21, 2018
Medical Communications Agenus, Gilead, Lexington, Massachusetts, USA, immuno-oncology, oncology

California-based firm Gilead Sciences and Massachusetts-based immuno-oncology biotech Agenus have announced that they have entered into a partnership focused on …

News
8643990124_7c11fee008_z

Gilead and Scholar Rock collaborate on fibrosis in deal worth more than $80m

December 20, 2018
Business Services, Research and Development Califonia, Gilead, Scholar Rock, USA, fibrosis

California-based antiviral drugs specialist Gilead Sciences has entered into a strategic partnership with Cambridge, Massachusetts-based biotech Scholar Rock as part …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025